Results 31 to 40 of about 1,640,663 (265)

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers [PDF]

, 2011
<p><b>Background:</b> Today, dementias are diagnosed late in the course of disease. Future treatments have to start earlier in the disease process to avoid disability requiring new diagnostic tools.
Jahn Holger, Thomas J Raedler, William Mullen, Kellmann Markus, Arlt Sönke, Eichenlaub, M., Zürbig Petra, Kellmann, M., Jahn, H., Wittke Stefan, Mischak Harald, Stefan Wittke, Mischak, H., Petra Zürbig, Thomas J. Raedler, Z, P., Mullen, W., Wittke, S., Holger Jahn, Mullen William, Wiedemann Klaus, Harald Mischak, Markus Kellmann, Klaus Wiedemann, Martin Eichenlaub, Raedler Thomas J., Sönke Arlt, Eichenlaub Martin   +27 more
core   +1 more source

Current Cancer Biomarkers

, 2023
Current Cancer Biomarkers is a comprehensive review on the status of biological markers for various types of cancer. It aims to update readers on current developments on the subject.
-
core   +1 more source

Characterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury

Biomarker Insights, 2012
After traumatic brain injury (TBI), glial fibrillary acidic protein (GFAP) and other brain-derived proteins and their breakdown products are released into biofluids such as CSF and blood.
J. Susie Zoltewicz, Dancia Scharf, Boxuan Yang, Aarti Chawla, Kimberly J. Newsom, Lijuan Fang   +5 more
doaj   +1 more source

Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy [PDF]

, 2010
Background: Urine proteome analysis is rapidly emerging as a tool for diagnosis and prognosis in disease states. For diagnosis of diabetic nephropathy (DN), urinary proteome analysis was successfully applied in a pilot study.
Navis, G.J., Zürbig, P., Fuchs, S., Winklhofer-Roob, B.M., Cerna Marie, Rossing Peter, Federici, M., Bakker Stephan J. L., Fischer Christine, Bakker, Stephan J. L.; id_orcid, Fuchs Sebastian, Zurbig, Petra, Rychlik, Ivan, Rychlík, I., Karel Medek, Navis, Gerjan J., Fischer, Christine, Cerna, Marie, Rossing, K., Gerjan J. Navis, Mischak Harald, Sebastian Fuchs, Stephan J L Bakker, Bilo Henk J. G., Mischak, H., Kasper Rossing, Medek, K., Rossing Kasper, PREDICTIONS Group, Bilo, H.J.G., Medek, Karel, null null, Fischer, C., Johannes M. Roob, Roob Johannes M., Alkhalaf, A., Mischak, Harald, Cerna, M., Janssen, Bart, Fuchs, Sebastian, Bakker, S.J.L., Johannes M Roob, Alaa Alkhalaf, Janssen, B., Bakker, Stephan J. L., Ivan Rychlík, Brigitte M. Winklhofer-Roob, Tiran, Beate, Rychlík Ivan, Roob, Johannes M., Zürbig Petra, Sourij, H., Tiran Beate, Bilo, Henk J. G., Rossing, Peter, Sourij Harald, Winklhofer-Roob, Brigitte M., Navis Gerjan J., Gerjan J Navis, Marie Cerna, Alkhalaf, Alaa, Henk J G Bilo, Christine Fischer, Petra Zürbig, Janssen Bart, Peter Rossing, Bart Janssen, Henk J. G. Bilo, Alkhalaf Alaa, Medek Karel, Harald Mischak, Stephan J. L. Bakker, Tiran, B., Rossing, P., Brigitte M Winklhofer-Roob, Sourij, Harald, Rossing, Kasper, Roob, J.M., Harald Sourij, Beate Tiran, Winklhofer-Roob Brigitte M.   +80 more
core   +3 more sources

Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer

, 2022
SIMPLE SUMMARY: Small cell lung cancer (SCLC) is an aggressive cancer representing 15% of all lung cancers. Unlike other types of lung cancer, treatments for SCLC have changed very little in the past 20 years and therefore, the survival rate remains low.
Anna Keogh, Stephen Finn, Keogh, Anna, Radonic, Teodora, Finn, Stephen, Teodora Radonic   +5 more
core   +1 more source

Scientific Profiles in the field of Biomarkers (2000-2010) [PDF]

, 2013
Biological marker is a term used in many scientific fields and was introduced as a measurable element or a clinical indicator in the abnormal biological processes, pathological condition, or pharmacological intervention.
Biglu, Mohammad-Hossein, Biglu, Sahar, Mehdi , Saberian-Brojeni, Giti, Shahmohammadi   +3 more
core   +1 more source

Emerging Biomarkers for Immunotherapy in Glioblastoma

, 2022
Immunotherapy has shown clinical benefits in several solid malignancies—in particular, melanoma and non-small cell lung cancer. However, in other solid tumours such as glioblastoma (GBM), the response to immunotherapy has been more variable, and ...
Nadia Mensali, Else Marit Inderberg
core   +1 more source

Profiling plasma peptides for the identification of potential ageing biomarkers in Chinese Han adults [PDF]

, 2012
Advancing age is associated with cardiovascular disease, diabetes mellitus and cancer, and shows significant inter-individual variability. To identify ageing-related biomarkers we performed a proteomic analysis on 1890 Chinese Han individuals, 1136 males
Manshu Song (153063), Xinwei Yu (153054), Feifei Zhao, Li, Y., Manshu Song, Jingjing Wu (153040), Alan H Bittles, Jiapeng Lu (153024), Zhang, Y., Jiapeng Lu, Wei Wang, Wang, Youxin, Yu, Xinwei, Meng, S., Wu, Jingjing, Song, Manshu, Huang, Y., Qingwei Ma (153058), Chang, Naibai, Shijiao Meng, Meng, Shijiao, Shijiao Meng (153050), Wang, Y., Naibai Chang, Xinwei Yu, Zhang, Youjun, Wang, Wei, Huang, Yuqing, Naibai Chang (153067), Yuqing Huang, Qingwei Ma, Yujun Zhang, Youxin Wang (153032), Yuqing Huang (153028), Alan H. Bittles (153071), Li, Yan, Yan Li (23143), Wei Wang (17594), Zhao, Feifei, Chang, N., Bittles, A.H., Yan Li, Song, M., Yujun Zhang (118792), Yu, X., Feifei Zhao (153044), Ma, Qingwei, Wu, J., Zhao, F., Lu, Jiapeng, Bittles, Alan H., Lu, J., Jingjing Wu, Ma, Q., Youxin Wang, Wang, W.   +55 more
core   +1 more source

Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases

Molecular Metabolism, 2021
Background: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and ...
Nina Sonne, Morten A. Karsdal, Kim Henriksen   +2 more
doaj   +1 more source

Biomarkers and Lung Cancer Early Detection: State of the Art

, 2021
Lung cancer burden is increasing, with 2 million deaths/year worldwide. Current limitations in early detection impede lung cancer diagnosis when the disease is still localized and thus more curable by surgery or multimodality treatment.
Fabrizio Bianchi, Tommaso Colangelo, Marinos Kallikourdis, Elisa Dama, Emanuela Fina, Marco Cremonesi, Giulia Veronesi   +6 more
core   +1 more source